Press Release
Novel Abbott Test That Aids in the Early Diagnosis of Acute Kidney Injury (AKI) Receives CE Mark
Protein Marker Test Aids in the Early Diagnosis of Kidney Injury and Reduces
Wait Time from Days to Hours
October 06, 2009
Abbott Park, Illinois (NYSE: ABT)
— Abbott announced today it has received CE Marking (Conformité Européene) for
a new diagnostic test that detects an important protein in urine, neutrophil
gelatinase-associated lipocalin (NGAL), an early marker or indicator for
patients with, or at risk of, acute kidney injury (AKI).
NGAL is a novel biomarker that can be detected in urine in as little as two
hours instead of days. Early detection can aid in the diagnosis of AKI -- a
common condition that can quickly progress to kidney failure if left untreated
-- and help physicians better manage patient care. Current tests lack the
clinical and timely precision that can help physicians intervene quickly and
mitigate the effect of any potential injury.
"Earlier and more accurate differential diagnosis of evolving AKI could
result in quicker changes in patient management to make potentially life-saving
therapeutic interventions and stop harmful progression," said Patrick
Murray, M.D., professor, University College Dublin and Mater Misericordiae
University Hospital.
Today AKI is diagnosed with a serum test to measure levels of creatinine, a
molecule that is generated from muscle metabolism. However, the test is neither
sensitive nor specific for detecting kidney injury. As much as half of normal
kidney function could be lost before serum creatinine elevations are detected.
This delay in diagnosis prevents physicians from intervening to regulate
medications or using hydration or blood pressure support in a timely manner to
lower the risk of patient harm.
"Published studies show that NGAL levels in patients with AKI are 30
times higher compared to normal patients, and urine NGAL measurements assist in
the specific and rapid diagnosis of AKI while creatinine blood tests are not
able to accurately distinguish AKI from chronic kidney disease," said
Sudarshan Hebbar, M.D., senior medical director, Abbott Diagnostics. "From
as little as a single drop of urine, we obtain vital information when time is
critical to improve patient management. Early information provided by the NGAL
urine test could make treatments more timely and effective and reduce costs due
to early intervention."
A landmark study published in Annals of Internal Medicine in May 2008
reported that urine NGAL can aid in distinguishing acute kidney injury from
other forms of kidney dysfunction in emergency room patients. The study showed
that urine NGAL is a highly sensitive and specific test that assists in the
differential diagnosis of AKI that helps distinguish acute injury from normal
kidney function, dehydration and chronic kidney disease.
Abbott's Urine NGAL assay is performed on the company's flagship automated
laboratory instrument, the ARCHITECT system. The test is now available to
hospital laboratories in a targeted group of European countries and will be
made more broadly available later this year.
About Acute Kidney Injury
AKI is a common and often devastating illness that quickly reduces the
ability of the kidneys to filter waste, a condition which can then progress to
kidney failure. Common causes of AKI include sepsis, major surgery, cardiogenic
shock, trauma and medications toxic to the kidneys. Prompt diagnosis of AKI is
critical in reducing mortality, which is as high as 80 percent in
post-operative settings. In addition, AKI predisposes those surviving to an
increased incidence of chronic kidney disease and end-stage renal disease.
About Abbott's Diagnostics Businesses
Abbott is a global leader in in vitro diagnostics and offers a broad
range of innovative instrument systems and tests for hospitals, reference labs,
molecular labs, blood banks, physician offices and clinics. With more than
69,000 institutional customers in more than 100 countries, Abbott's diagnostic
products offer customers automation, convenience, bedside testing, cost
effectiveness and flexibility. Abbott has helped transform the practice of
medical diagnosis from an art to a science through the company's commitment to
improving patient care. The history of Abbott is filled with examples of
first-of-a-kind diagnostic products and significant technological and research
advancements.
About Abbott
Abbott (NYSE: ABT)
is a global, broad-based health care company devoted to the discovery,
development, manufacture and marketing of pharmaceuticals and medical products,
including nutritionals, devices and diagnostics. The company employs more than
72,000 people and markets its products in more than 130 countries.
ARCHITECT and ARCHITECT Urine NGAL are Abbott trademarks in various
jurisdictions
Media:
Don Braakman |
(847) 937-0080 |
Financial:
Tina Ventura |
(847) 935-9390 |
